Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma (Q37508003)

20 August 2017

1 reference

title

Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma (English)

1 reference

20 August 2017

Stéphane Oudard

1 reference

20 August 2017

Jacques Medioni

1 reference

20 August 2017

Jorge Aylllon

1 reference

20 August 2017

Eduardo Barrascourt

1 reference

20 August 2017

Reza-Thierry Elaidi

1 reference

20 August 2017

José Balcaceres

1 reference

20 August 2017

Florian Scotte

1 reference

20 August 2017

publication date

1 June 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

published in

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

page(s)

705-717

1 reference

Global cancer statistics, 2002

20 August 2017

cites work

1 reference

The changing pattern of kidney cancer incidence and mortality in Europe

21 January 2018

1 reference

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

21 January 2018

1 reference

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

21 January 2018

1 reference

Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?

21 January 2018

1 reference

Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome

21 January 2018

1 reference

Treatment options in renal cell carcinoma: past, present and future

21 January 2018

1 reference

Update on the medical treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

21 January 2018

1 reference

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

21 January 2018

1 reference

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Recent advances in the therapy of renal cancer

21 January 2018

1 reference

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial

21 January 2018

1 reference

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis

21 January 2018

1 reference

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

21 January 2018

1 reference

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

21 January 2018

1 reference

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy

21 January 2018

1 reference

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

21 January 2018

1 reference

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients

21 January 2018

1 reference

Outcome after surgical resections of recurrent chest wall sarcomas

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Patterns of pulmonary complications associated with sirolimus

21 January 2018

1 reference

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

21 January 2018

1 reference

Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.27

1 reference

20 August 2017

1 reference